21 – 30 of 202
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
ESMO Clinical Practice Guideline interim update on new targeted therapies in the first line and at relapse of chronic lymphocytic leukaemia☆
- Contribution to journal › Article
-
Mark
Quantification and Profiling of Early and Late Differentiation Stage T Cells in Mantle Cell Lymphoma Reveals Immunotherapeutic Targets in Subsets of Patients
- Contribution to journal › Article
-
Mark
Omission of Radiotherapy in Primary Mediastinal B-Cell Lymphoma: IELSG37 Trial Results
- Contribution to journal › Article
-
Mark
MYC protein is a high-risk factor in mantle cell lymphoma and identifies cases beyond morphology, proliferation and TP53/p53 – a Nordic Lymphoma Group study
- Contribution to journal › Article
-
Mark
The CNS relapse in T-cell lymphoma index predicts CNS relapse in patients with T- and NK-cell lymphomas
- Contribution to journal › Article
-
Mark
CD163+ macrophages in mantle cell lymphoma induce activation of prosurvival pathways and immune suppression
- Contribution to journal › Article
-
Mark
Infections in patients with mantle cell lymphoma
- Contribution to journal › Article
-
Mark
Body mass index and risk of over 100 cancer forms and subtypes in 4.1 million individuals in Sweden : the Obesity and Disease Development Sweden (ODDS) pooled cohort study
- Contribution to journal › Article
-
Mark
The National Swedish Lymphoma Register – a systematic validation of data quality
- Contribution to journal › Article
-
Mark
Outcomes for patients with secondary CNS involvement in relapsed/refractory diffuse large B-cell lymphoma and estimation of eligibility for CAR T-cell therapy
- Contribution to journal › Letter
